Sjogren's syndrome: cross-border specialty drug access for international patients

Quick orientation

Primary Sjogren's syndrome affects an estimated 0.5 to 1 percent of adults, with strong female predominance. Secondary Sjogren's syndrome occurs in the context of other autoimmune diseases.

Typical age of onset. Most commonly diagnosed between ages 40 and 60.

Severity tiers. Severity ranges from sicca symptoms alone to systemic disease with extraglandular manifestations.

Why specialty drugs for Sjogren's syndrome are hard to access internationally

Disease-modifying therapy for Sjogren's syndrome has lagged other autoimmune diseases. Several recent trials of B-cell-directed and other immunomodulators are influencing off-label use; targeted approvals remain limited.

Treatments approved by the FDA

• Tryptyr (acoltremon ophthalmic solution) — FDA approval: 2025. Mechanism: TRPM8 agonist for dry eye disease (relevant for Sjogren's-associated dry eye). Route: Topical ophthalmic twice daily. US WAC ballpark: Approximately USD 800 to 1,200 per month. Country pricing: UAE · Bahrain · Oman.
• Miebo (perfluorohexyloctane ophthalmic solution) — FDA approval: 2023. Mechanism: Anti-evaporative ocular surface drop (relevant for Sjogren's-associated dry eye). Route: Topical ophthalmic four times daily. US WAC ballpark: Approximately USD 800 to 1,200 per month. Country pricing: Saudi Arabia · Kuwait · Jordan · Bahrain · Lebanon.
• Salagen (pilocarpine) — FDA approval: 1994. Mechanism: Muscarinic receptor agonist for xerostomia. Route: Oral. US WAC ballpark: Variable, often generic.

Cross-border pathways used for Sjogren's syndrome

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm Sjogren's syndrome diagnosis using established criteria.
• Document organ involvement and antibody profile.
• Coordinate with rheumatology and ophthalmology.
• Screen for lymphoma risk in long-standing disease.
• Address sicca symptoms, fatigue, and systemic features.

Common questions

Is there a disease-modifying therapy for Sjogren's?

Targeted approvals remain limited. Most therapy addresses symptoms; some patients receive off-label immunomodulators under specialist guidance.

Are these dry eye products available locally?

Newer products are in early international rollout.

How long does shipment take?

Five to ten business days from prescription receipt.

What documents are required?

Rheumatologist or ophthalmologist's prescription and clinical summary.

Can I combine therapies?

Many patients combine ocular and oral therapies for symptom relief.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Sjogren's syndrome, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Sjogren's syndrome

Reserved for you.